Equities research analysts predict that R1 RCM Inc. (NASDAQ:RCM - Get Rating) will announce sales of $400.20 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for R1 RCM's earnings. The lowest sales estimate is $383.90 million and the highest is $411.79 million. R1 RCM reported sales of $353.40 million during the same quarter last year, which indicates a positive year over year growth rate of 13.2%. The business is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that R1 RCM will report full year sales of $1.70 billion for the current financial year, with estimates ranging from $1.69 billion to $1.71 billion. For the next fiscal year, analysts anticipate that the business will report sales of $1.96 billion, with estimates ranging from $1.90 billion to $2.01 billion. Zacks' sales calculations are a mean average based on a survey of sell-side research analysts that follow R1 RCM.
R1 RCM (NASDAQ:RCM - Get Rating) last released its earnings results on Monday, May 9th. The healthcare provider reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The firm had revenue of $385.70 million for the quarter, compared to analyst estimates of $384.18 million. R1 RCM had a net margin of 6.64% and a return on equity of 29.44%. The business's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.37) EPS.
A number of equities analysts recently issued reports on the company. Robert W. Baird increased their target price on R1 RCM from $29.00 to $32.00 in a report on Thursday, March 3rd. Zacks Investment Research cut R1 RCM from a "buy" rating to a "hold" rating in a report on Friday. TheStreet upgraded R1 RCM from a "d" rating to a "c" rating in a report on Monday, May 9th. Guggenheim assumed coverage on R1 RCM in a report on Wednesday, April 13th. They issued a "neutral" rating on the stock. Finally, Deutsche Bank Aktiengesellschaft cut their target price on R1 RCM from $30.00 to $28.00 in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $29.25.
A number of hedge funds have recently bought and sold shares of the business. Twin Tree Management LP purchased a new stake in R1 RCM in the first quarter worth about $28,000. Cordasco Financial Network purchased a new stake in shares of R1 RCM during the first quarter worth about $36,000. Point72 Hong Kong Ltd purchased a new stake in shares of R1 RCM during the fourth quarter worth about $53,000. Strs Ohio purchased a new stake in shares of R1 RCM during the first quarter worth about $69,000. Finally, PrairieView Partners LLC purchased a new stake in shares of R1 RCM during the fourth quarter worth about $107,000. 41.97% of the stock is currently owned by institutional investors.
R1 RCM stock opened at $22.52 on Friday. The stock has a market capitalization of $6.30 billion, a price-to-earnings ratio of 72.65, a PEG ratio of 2.25 and a beta of 0.86. R1 RCM has a 52-week low of $18.71 and a 52-week high of $27.86. The stock's 50 day moving average price is $24.79 and its two-hundred day moving average price is $24.49. The company has a debt-to-equity ratio of 2.06, a quick ratio of 1.43 and a current ratio of 1.54.
About R1 RCM (Get Rating)
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.
Get a free copy of the Zacks research report on R1 RCM (RCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider R1 RCM, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and R1 RCM wasn't on the list.
While R1 RCM currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here